We are live on ! Find out more
SABSW icon

SAB Biotherapeutics Warrant
SABSW

7 hedge funds and large institutions have $28.1K invested in SAB Biotherapeutics Warrant in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.19% less ownership

Funds ownership: 9.53% → 9.34% (-0.19%)

22% less funds holding

Funds holding: 9 → 7 (-2)

58% less capital invested

Capital invested by funds: $66.3K → $28.1K (-$38.2K)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
7
Holders Change
-2
Holders Change %
-22.22%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
3
Closed
2
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
-$3K

Top Buyers

Rank Fund Capital Flow
1
HWM
HB Wealth Management
Georgia
+$559

Top Sellers

Rank Fund Capital Flow
1
YCM
Yakira Capital Management
Connecticut
-$810
2
Walleye Trading
Walleye Trading
New York
-$386
3
WAM
Wolverine Asset Management
Illinois
-$226
4
UBS Group
UBS Group
Switzerland
-$122
5
TRCT
Tower Research Capital (TRC)
New York
-$4

SABSW Hedge Fund Activity: Q1 2025 in Review

7 of the 7,475 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q1 2025, worth a combined $28.1K — down 58% from $66.3K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of SABSW and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was HB Wealth Management, adding an estimated $559. The largest seller was Yakira Capital Management, cutting an estimated $810.

  • 7 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q1 2025, down from 9 in Q4 2024.
  • Funds reported $28.1K of SAB Biotherapeutics Warrant stock for Q1 2025, down 58% quarter-over-quarter.
  • 0 funds opened new SAB Biotherapeutics Warrant positions in Q1 2025 and 2 closed out, a net change of -2 holders.
  • The largest SAB Biotherapeutics Warrant buyer in Q1 2025 was HB Wealth Management, an estimated $559 added.
  • The largest SAB Biotherapeutics Warrant seller in Q1 2025 was Yakira Capital Management, an estimated $810 sold.

Based on aggregated 13F filings for Q1 2025.